Drug Profile
Branaplam - Novartis
Alternative Names: Branaplam hydrochloride - Novartis; LMI 070; NVP-LMI070-AAA; NVP-LMI070-NX; NVS-SM1Latest Information Update: 11 Dec 2023
Price :
$50
*
At a glance
- Originator Novartis
- Class Cyclohexanes; Piperidines; Pyrazoles; Pyridazines; Small molecules
- Mechanism of Action Survival of motor neuron 2 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Spinal muscular atrophy
- Phase I Unspecified
- Discontinued Huntington's disease
Most Recent Events
- 27 Oct 2023 Novartis completes a phase II trial in Huntington's disease (In adults, In the elderly) in USA Germany, Hungary, Spain, France, Belgium, Canada, Italy, the US and the UK(PO) (NCT05111249)
- 06 Feb 2023 Discontinued - Phase-II for Huntington's disease (In the elderly, In adults) in Belgium (PO)
- 06 Feb 2023 Discontinued - Phase-II for Huntington's disease (In the elderly, In adults) in Canada (PO)